Table 1. Characteristics of included studies.
| Study | Procedures | ASA | Patient number | Intervention |
|---|---|---|---|---|
| Zhang et al. (2022b) | Hysteroscopy | I–II | 90 | Propofol 5 mg/kg/h (n = 30) |
| Remit 0.48 mg/kg/h (n = 30) | ||||
| Remit 0.6 mg/kg/h (n = 30) | ||||
| Guo et al. (2022a) | Gastrointestinal endoscopy | I–II | 77 | Propofol 1.5 mg/kg (n = 38) |
| Remit 0.15 mg/kg (n = 39) | ||||
| Guo et al. (2022b) | Colonoscopy | I–II | 248 | Propofol 1.5 mg/kg (n = 124) |
| Remin 5 mg/kg (n = 124) | ||||
| Shi et al. (2022) | Endoscopic Variceal Ligation | II–III | 76 | Propofol 4–10 mg/kg/h (n = 38) |
| Remit 1–2 mg/kg/h (n = 38) | ||||
| Zhang, Li & Liu (2021) | Hysteroscopy | I–II | 82 | Propofol 3–6 mg/kg/h (n = 41) |
| Remib 1 mg/kg/h (n = 41) | ||||
| Chen et al. (2020) | Colonoscopy | I–II | 384 | Propofol 1.5 mg/kg (n = 190) |
| Remit 5.0 mg (n = 194) | ||||
| Chen et al. (2020) | Upper gastrointestinal endoscopy | I–II | 378 | Propofol 1.5 mg/kg (n = 189) |
| Remit 5.0 mg (n = 189) | ||||
| Cao et al. (2022) | Gastroscopy: | II–III | 148 | Propofol: 2 mg/kg (n = 74) |
| Remit: 0.107 mg/kg (n = 74) | ||||
| (Sufentanil 0.15 µg/kg) | ||||
| Qiu et al. (2022) | Endoscopic submucosal dissection | I–III | 56 | Propofol: 2.0 mg/kg (n = 28) |
| Remin: 0.3 mg/kg (n = 28) | ||||
| Tan et al. (2022) | Gastrointestinal endoscopy | I–II | 99 | Propofol 1–1.5 mg/kg (n = 33) |
| Remit 0.1 mg/kg (n = 33) | ||||
| Remit 0.2 mg/kg (n = 33) | ||||
| Yao et al. (2022) | Colonoscopy | I–II | 132 | Propofol 1 mg/kg (n = 66) |
| Remin 0.2 mg/kg (n = 66) | ||||
| Lu et al. (2022) | Upper gastrointestinal endoscopy | I–III | 400 | Propofol 3 g/h (n = 200) |
| Remit: 300 mg/h (n = 200) |
Notes.
- ASA
- American Society of Anesthesiologists classification
- remib
- remimazolam besilate
- remit
- remimazolam tosilate
- remin
- substituent not reported